Postinflammatory hyperpigmentation - Postinflamatorna Hiperpigmentacija
Postinflamatorna Hiperpigmentacija (Postinflammatory hyperpigmentation) je stanje kože, za katero je značilno povečanje pigmenta v koži po vnetju kože. postinflamatorna hiperpigmentacija (postinflammatory hyperpigmentation) lahko povzroči dolgotrajna izpostavljenost soncu, vnetje ali druge poškodbe kože, vključno s tistimi, povezanimi z aknami. Ljudje s temnejšo poltjo so običajno bolj nagnjeni k hiperpigmentaciji zaradi pretirane izpostavljenosti soncu.
☆ V rezultatih raziskave Stiftung Warentest iz Nemčije leta 2022 je bilo zadovoljstvo potrošnikov z ModelDermom le nekoliko nižje kot s plačanimi telemedicinskimi svetovanji.
References
Postinflammatory hyperpigmentation (PIH) je pogosta težava s kožo, ki se pojavi po vnetju ali poškodbi kože. Običajno traja dolgo časa in je slabše pri ljudeh s temnejšo poltjo (Fitzpatrick skin types III–VI) . Čeprav se pogosto izboljša samo od sebe, lahko traja nekaj časa, zato je zdravljenje pogosto potrebno dolgo časa. Najbolje deluje kombiniranje različnih zdravljenj.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation je pogosta posledica vnetja kože. Resneje in pogosteje prizadene posameznike s temnejšo poltjo. Študije kažejo, da so težave, kot je postinflammatory hyperpigmentation , med glavnimi razlogi, zakaj ljudje s temnejšo poltjo iščejo dermatološko oskrbo. Zgodnje zdravljenje je ključnega pomena za razrešitev postinflammatory hyperpigmentation in se običajno začne z obvladovanjem začetnega vnetnega stanja. Prva linija zdravljenja običajno vključuje uporabo lokalnih sredstev, ki posvetlijo kožo, skupaj s kremo za sončenje za zaščito. Ta sredstva, tako kot hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , lahko učinkovito zmanjšajo prekomerno pigmentacijo. Poleg tega se retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy uporabljajo tudi kot sredstva za depigmentacijo, pri čemer se pojavljajo nova zdravljenja. Medtem ko so lokalna zdravljenja običajno učinkovita pri površinski hiperpigmentaciji, bodo morda potrebni postopki (laser, chemical peel) pri trdovratnih primerih. Pomembno je, da ste pri teh zdravljenjih previdni, da se izognete draženju in poslabšanju postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
